New Jersey cancer center features green lobby

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 12
Volume 19
Issue 12

The John Theurer Cancer Center at Hackensack University Medical Center in New Jersey opened its new $130-million comprehensive care facility.

The John Theurer Cancer Center at Hackensack University Medical Center in New Jersey opened its new $130-million comprehensive care facility. The cancer center building will house 14 specialized divisions, including research and auxiliary oncology services, nutrition counseling, psychosocial support, and complementary therapies. The centerpiece of the lobby is a “living wall” with a 24-foot waterfall and more than 30 hydroponically grown plant species (above). The project was funded with $65 million raised by the Hackensack University Medical Center and with a $10 million donation from Helena Theurer, in memory of her husband John Theurer.

Articles in this issue
Roche Gains OK in Europe for Rituximab for Maintenance
JAK inhibitor quells symptoms linked to myelofibrosis
E-Charts help track course of febrile events in hematology
E-Charts help track course of febrile events in hematology
Colon Cancer Patients With p.G13D KRAS Mutations See Better Survival With Cetuximab-Based Therapy
Colon Cancer Patients With p.G13D KRAS Mutations See Better Survival With Cetuximab-Based Therapy
Duke Cancer Center Lands Renewal of $30 Million Grant
Even Insured Cancer Patients May Stumble Over Co-pays and Drug Costs
Even Insured Cancer Patients May Stumble Over Co-pays and Drug Costs
New Jersey cancer center features green lobby
New Jersey cancer center features green lobby
Long Constitutional Telomere Length May Serve as Measure for Colon Cancer Risk in Younger Patients
Long Constitutional Telomere Length May Serve as Measure for Colon Cancer Risk in Younger Patients
Short Course of Radiation Therapy Before Total Mesorectal Excision Lowers Local Recurrence Rate
Short Course of Radiation Therapy Before Total Mesorectal Excision Lowers Local Recurrence Rate
Growing number of pts undergo radiotherapy
Low-intensity electric-field Rx boosts chemo in NSCLC
Melanoma: Rose Bengal Scores, Ipilimumab Sees Delay
Melanoma: Rose Bengal Scores, Ipilimumab Sees Delay
Postgastrectomy Patients May Benefit From HP Eradication Rx
Postgastrectomy Patients May Benefit From HP Eradication Rx
Post-lumpectomy RT lowers risk of recurrence
Post-lumpectomy RT lowers risk of recurrence
CMS: Provenge shows evidence of ‘moderate’ benefit
CMS: Provenge shows evidence of ‘moderate’ benefit

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.